Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.2 | 0.0004 |
mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.19 | 0.001 |
mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.096 | 0.004 |
mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.01 |
mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.01 |
mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.1 | 0.01 |
mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.02 |
mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.14 | 0.02 |